- Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 2020;38(16):1763-1773.
Findings
What does this study add?
- At a median follow-up of 59 months, OS was greater in the neoadjuvant chemoradiotherapy group (15.7 months) than in the upfront surgery group (14.3 months) (HR, 0.73; 95% CI, 0.56-0.96; P=0.025).
- The 5-year OS rate was 20.5% (95% CI, 14.2-29.8) with neoadjuvant chemoradiotherapy compared to 6.5% (95% CI, 3.1-13.7) with upfront surgery.
- The effect of neoadjuvant chemoradiotherapy was consistent across the prespecified subgroups, including resectable and borderline resectable pancreatic cancer.
- The secondary outcomes of disease-free survival and locoregional failure-free interval, as well as pathologic outcomes were also significantly better with the neoadjuvant approach.
